ME00459B - Aril fuzirana azapoliciklična jedinjenja - Google Patents

Aril fuzirana azapoliciklična jedinjenja

Info

Publication number
ME00459B
ME00459B MEP-2008-702A MEP70208A ME00459B ME 00459 B ME00459 B ME 00459B ME P70208 A MEP70208 A ME P70208A ME 00459 B ME00459 B ME 00459B
Authority
ME
Montenegro
Prior art keywords
compounds
aryl fused
fused azapolycyclic
azapolycyclic compounds
aryl
Prior art date
Application number
MEP-2008-702A
Other languages
English (en)
Inventor
Jotham Wadsworth Coe
Paige Roanne Palmer Brooks
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22094096&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME00459(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ME00459B publication Critical patent/ME00459B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/24—Camphidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Traži se zaštita za jedinjenja formule I i njihovefarmaceutski prihvatljive soli, gde R 1 , R 2 , R 3 i n su kao što je definisano u specifikaciji, intermedijari u sintezi datihjedinjenja, farmaceutski preparati koji sadrže ova jedinjenja i postupciza upotrebu datih jedinjenja u lečenju neuroloških i fiziološkihporemećaja.
MEP-2008-702A 1997-12-31 1998-11-13 Aril fuzirana azapoliciklična jedinjenja ME00459B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7024597P 1997-12-31 1997-12-31
PCT/IB1998/001813 WO1999035131A1 (en) 1997-12-31 1998-11-13 Aryl fused azapolycyclic compounds

Publications (1)

Publication Number Publication Date
ME00459B true ME00459B (me) 2011-10-10

Family

ID=22094096

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2008-702A ME00459B (me) 1997-12-31 1998-11-13 Aril fuzirana azapoliciklična jedinjenja

Country Status (52)

Country Link
US (6) US6410550B1 (me)
EP (2) EP1659114A3 (me)
JP (1) JP3550359B2 (me)
KR (1) KR100408138B1 (me)
CN (2) CN1324013C (me)
AP (1) AP1170A (me)
AR (1) AR017967A1 (me)
AT (1) ATE386024T1 (me)
AU (1) AU753389C (me)
BG (1) BG65058B1 (me)
BR (2) BR9816186B1 (me)
CA (1) CA2316921C (me)
CO (1) CO4810373A1 (me)
CY (2) CY1107391T1 (me)
CZ (1) CZ301925B6 (me)
DE (2) DE122008000038I1 (me)
DK (1) DK1044189T4 (me)
DZ (1) DZ2697A1 (me)
EA (1) EA003190B1 (me)
EG (1) EG23816A (me)
ES (1) ES2301210T5 (me)
FR (1) FR08C0039I2 (me)
GT (2) GT199800200A (me)
HK (1) HK1031878A1 (me)
HN (1) HN1998000177A (me)
HR (2) HRP20000445B1 (me)
HU (2) HU230297B1 (me)
IL (2) IL136727A0 (me)
IS (1) IS5514A (me)
LU (1) LU91442I2 (me)
MA (1) MA26589A1 (me)
ME (1) ME00459B (me)
MY (1) MY118163A (me)
NL (1) NL300355I2 (me)
NO (2) NO319115B1 (me)
NZ (1) NZ504482A (me)
OA (1) OA11428A (me)
PA (1) PA8463901A1 (me)
PE (1) PE20000053A1 (me)
PL (1) PL209404B1 (me)
PT (1) PT1044189E (me)
RS (1) RS50069B (me)
SA (1) SA99191123B1 (me)
SG (1) SG102686A1 (me)
SI (1) SI1044189T2 (me)
SK (1) SK286886B6 (me)
TN (1) TNSN98237A1 (me)
TR (1) TR200001840T2 (me)
TW (1) TW513412B (me)
UA (1) UA66825C2 (me)
WO (1) WO1999035131A1 (me)
ZA (1) ZA9811911B (me)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA003190B1 (ru) * 1997-12-31 2003-02-27 Пфайзер Продактс Инк. Азаполициклические соединения, конденсированные с арилом
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
BR0012793A (pt) 1999-07-28 2002-04-30 Univ Leland Stanford Junior Métodos para indução de angiogênese pela administração de nicotina ou outro agonista de receptor de nicotina
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20020010192A1 (en) * 2000-06-02 2002-01-24 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
DK1383733T3 (da) * 2001-04-20 2008-06-09 Pfizer Prod Inc Fremgangsmåde til fremstilling af 1,3-substituerede indener og aryl-sammenföjede azapolycykliske forbindelser
DOP2002000390A (es) * 2001-05-14 2003-03-15 Pfizer Prod Inc Sal citrato de 5,8 14-hiezatetraciclo [10.3.1.0 2,11. 0.4.9] hexadeca-2(11),3,5,8,9, pentaeno y composiciones farmaceuticas de las mismas
JP3779682B2 (ja) * 2001-05-14 2006-05-31 ファイザー・プロダクツ・インク ５，８，１４−トリアザテトラシクロ［１０．３．１．０２，１１．０４，９］−ヘキサデカ−２（１１），３，５，７，９−ペンタンの酒石酸塩及びその医薬組成物
CA2468705A1 (en) * 2001-11-29 2003-06-05 Pfizer Products Inc. Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
EP1451202B1 (en) 2001-11-30 2008-08-20 Pfizer Products Inc. Aryl fused azapolycyclic compounds
DE60218885T2 (de) * 2001-11-30 2008-01-17 Pfizer Products Inc., Groton Orale pharmazeutische Arzneiformen bzw. Dosierungsformen von 5,8,14-Triazatetra-cyclo-(10.3.1.0 (2,11).0(4,9)-hexadeca-2(11),3,5,7,9-pentaen mit kontrollierter Freisetzung
DK1572127T4 (da) 2002-02-14 2014-11-24 Univ Leland Stanford Junior Enzymbehandling af fødevarer til cøliaki
US7320788B2 (en) * 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
US8143210B2 (en) * 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7462688B2 (en) * 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
WO2003096979A2 (en) * 2002-05-14 2003-11-27 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7265093B2 (en) * 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
US7202216B2 (en) * 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
DK1565421T3 (da) * 2002-11-20 2008-09-22 Pfizer Prod Inc Fremgangsmåde til fremstilling af indan -1,3-dicarboxylsyre
DK1563300T3 (da) * 2002-11-20 2012-07-23 Univ Leland Stanford Junior Diagnostisk fremgangsmåde til cøliaki
WO2004048318A1 (en) * 2002-11-25 2004-06-10 Pfizer Products Inc. Improved process for the preparation of 1,3-substituted indenes
KR20050101177A (ko) * 2003-01-15 2005-10-20 화이자 프로덕츠 인크. 아릴 융합된 폴리시클릭 락탐의 제조 방법
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
EP1633358A1 (en) * 2003-05-20 2006-03-15 Pfizer Products Inc. Pharmaceutical compositions of varenicline
DE602004015986D1 (de) * 2003-06-04 2008-10-02 Pfizer Prod Inc Herstellung von substituierten chinoxalinen aus den dianilinen mit 2,3-dihydroxy-1,4-dioxan
CA2533100A1 (en) * 2003-07-21 2005-01-27 Pfizer Products Inc. Aryl fused azapolycyclic compounds
ATE443705T1 (de) * 2003-07-21 2009-10-15 Pfizer Prod Inc Nikotin abhängigkeit reduzierende heteroaryl kondensierte azapolycyclische verbindungen
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050043406A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US7579313B2 (en) * 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US7563864B2 (en) * 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
US7534426B2 (en) * 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
US7628985B2 (en) * 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
WO2006006071A1 (en) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution of an aryl-fused azapolycyclic compound
US7766018B2 (en) * 2004-09-30 2010-08-03 Smoke-Break, Inc. Device and composition for reducing the incidence of tobacco smoking
JP2008531540A (ja) * 2005-02-24 2008-08-14 ファイザー・プロダクツ・インク 高純度置換キノキサリンの調製
US20060211649A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of cytisine for enhancing physical performance
WO2007076875A2 (en) * 2006-01-06 2007-07-12 Aarhus Universitet Compounds acting on the serotonin transporter
AU2007231072A1 (en) * 2006-03-27 2007-10-04 Pfizer Products Inc. Varenicline standards and impurity controls
CA2650211A1 (en) * 2006-04-24 2007-11-01 Prizer Products Inc. Asymmetric membranes for drug delivery devices
US20100234349A1 (en) 2006-09-04 2010-09-16 Olsen Gunnar M Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
WO2008060487A2 (en) * 2006-11-09 2008-05-22 Pfizer Products Inc. Polymorphs of nicotinic intermediates
EP2136833B1 (en) * 2007-03-16 2019-05-01 The Board of Trustees of the Leland Stanford Junior University Combination enzyme therapy for digestion of dietary gluten
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline
WO2009101185A2 (en) * 2008-02-15 2009-08-20 Medichem, S.A. A NEW POLYMORPHIC FORM OF A PYRAZINO[2,3-h][3] BENZAZEPINE DERIVATIVE
US20090215787A1 (en) * 2008-02-22 2009-08-27 Mai De Ltd. Preparations of new polymorphic forms of varenicline tartrate
US9463190B2 (en) * 2008-03-31 2016-10-11 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
WO2009143347A2 (en) * 2008-05-22 2009-11-26 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318460A1 (en) * 2008-05-26 2009-12-24 Glenmark Amorphous varenicline tartrate and process for the preparation thereof
WO2009155403A2 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) * 2008-07-10 2010-01-14 Revital Lifshitz-Liron Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
EP2334679A1 (en) * 2008-09-01 2011-06-22 Actavis Group PTC EHF Process for preparing varenicline, varenicline intermediates, and pharmaceutically acceptable salts thereof
EP2204369A1 (en) 2008-12-22 2010-07-07 Medichem, S.A. Process for preparing varenicline and intermediates for use therein
US8063032B2 (en) 2009-02-11 2011-11-22 Sunovion Pharmaceuticals Inc. Histamine H3 inverse agonists and antagonists and methods of use thereof
EP2440187A2 (en) 2009-06-10 2012-04-18 Actavis Group PTC ehf. Amorphous varenicline tartrate co-precipitates
WO2010151524A1 (en) 2009-06-22 2010-12-29 Teva Pharmaceutical Industries Ltd Solid states forms of varenicline salts and processes for preparation thereof
MX2012002827A (es) * 2009-09-11 2012-04-10 Sunovion Pharmaceuticals Inc Agonistas inversos y antagonistas de histamina h3 y metodos para usar los mismos.
WO2011110954A1 (en) 2010-03-09 2011-09-15 Actavis Group Ptc Ehf Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity
KR101109389B1 (ko) * 2010-04-30 2012-01-30 삼성전기주식회사 인쇄회로기판 및 그 제조방법
WO2011140431A1 (en) 2010-05-06 2011-11-10 Teva Pharmaceutical Industries Ltd. Varenicline salts and crystal forms thereof
US20120004239A1 (en) 2010-06-11 2012-01-05 Medichem, S.A. Process for Preparing Quinoxaline Derivatives
JPWO2013002365A1 (ja) 2011-06-30 2015-02-23 東レ株式会社 止痒剤
ITMI20111413A1 (it) * 2011-07-28 2013-01-29 Dipharma Francis Srl Procedimento per la preparazione di vareniclina
ES2426838B1 (es) 2012-04-20 2014-05-07 Genetracer Biotech S.L Método para predecir el éxito en el abandono del consumo de tabaco en respuesta a un tratamiento farmacológico
ES2426517B1 (es) 2012-04-20 2014-05-14 Genetracer Biotech S.L Método para predecir la seguridad de un tratamiento farmacológico
CN103570502A (zh) * 2012-07-18 2014-02-12 上海科胜药物研发有限公司 一种伐伦克林中间体的制备方法
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
CN103992272B (zh) * 2014-06-09 2016-05-11 安徽省逸欣铭医药科技有限公司 一种盐酸喷他佐辛酯、其制备方法及其用途
KR20160126697A (ko) 2015-04-24 2016-11-02 한미정밀화학주식회사 신규 결정형의 바레니클린 옥살산 염 수화물, 이의 제조방법, 및 이를 포함하는 약학 조성물
KR20160143407A (ko) 2015-06-05 2016-12-14 한미정밀화학주식회사 신규한 바레니클린 뮤케이트 염, 이의 결정형 및 이의 제조방법
KR101724301B1 (ko) 2016-11-22 2017-04-10 주식회사 한서켐 바레니클린 살리실산염의 i형 결정 및 그 제조방법
CN106674194B (zh) * 2016-12-14 2019-03-05 山东省联合农药工业有限公司 一种结构新颖的烟碱类杀虫剂及其制备方法和用途
TWI775817B (zh) 2017-03-03 2022-09-01 南韓商西梯茜生命工學股份有限公司 包含伐尼克蘭或其藥學上可接受鹽類的內含錯合物的口服藥物製劑
KR102463733B1 (ko) 2017-06-30 2022-11-04 한미약품 주식회사 함량 균일성 및 안정성이 향상된 바레니클린 옥살산염이 포함된 약제학적 조성물
WO2018154395A2 (en) 2018-06-11 2018-08-30 Alvogen Malta Operations (Row) Ltd Controlled release pharmaceutical composition of varenicline
KR20200034293A (ko) 2018-09-21 2020-03-31 한미약품 주식회사 제어 방출용 바레니클린 제제
TW202206078A (zh) 2020-04-28 2022-02-16 美商奧伊斯特普安生物製藥公司 局部投與菸鹼乙醯膽鹼受體促效劑用以抑制冠狀病毒感染
CN113956255A (zh) * 2020-07-20 2022-01-21 威智医药有限公司 一种伐尼克兰中间体、伐尼克兰及其盐的制备方法
WO2022035434A1 (en) 2020-08-14 2022-02-17 Almatica Pharma Llc Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof
US11040983B1 (en) 2020-08-14 2021-06-22 Almatica Pharma Llc Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof
WO2022147189A1 (en) * 2020-12-30 2022-07-07 Antares Pharma, Inc. Varenicline prodrugs
WO2022222019A1 (en) * 2021-04-20 2022-10-27 Suzhou Fude Zhaofeng Biochemical Technology Co., Ltd Total synthesis of varenicline
CN113277993B (zh) * 2021-06-06 2023-07-21 湖南第一师范学院 一种Tafamidis及其衍生物的合成方法
WO2023275413A2 (en) 2021-12-23 2023-01-05 Medichem, S.A. Solid pharmaceutical formulations of varenicline
EP4241775A1 (en) 2022-03-11 2023-09-13 Par Pharmaceutical, Inc. Tablet comprising varenicline and process of preparation thereof
US11602537B2 (en) 2022-03-11 2023-03-14 Par Pharmaceutical, Inc. Varenicline compound and process of manufacture thereof
WO2023244584A1 (en) 2022-06-14 2023-12-21 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use
WO2024095172A1 (en) 2022-11-04 2024-05-10 Pfizer Inc. Prodrugs of varenicline and compounds containing vulnerable amines

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) * 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
CH644116A5 (de) * 1980-08-21 1984-07-13 Hoffmann La Roche Imidazolderivate.
EP0853621A1 (en) † 1995-09-22 1998-07-22 Novo Nordisk A/S Novel substituted azacyclic or azabicyclic compounds
EA003190B1 (ru) * 1997-12-31 2003-02-27 Пфайзер Продактс Инк. Азаполициклические соединения, конденсированные с арилом
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
AU1918299A (en) * 1998-02-23 1999-09-06 Warner-Lambert Company Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
EP0955301A3 (en) * 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
SK15952000A3 (sk) * 1998-04-29 2002-06-04 Pfizer Products Inc. Aryl-anelovaná azapolycyklická zlúčenina, jej použitie a farmaceutické kompozície na jej báze
ATE394401T1 (de) * 1999-01-29 2008-05-15 Abbott Lab Diazabicycloderivate als nikotin-acetylcholin- rezeptorliganden
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
JP3779682B2 (ja) * 2001-05-14 2006-05-31 ファイザー・プロダクツ・インク ５，８，１４−トリアザテトラシクロ［１０．３．１．０２，１１．０４，９］−ヘキサデカ−２（１１），３，５，７，９−ペンタンの酒石酸塩及びその医薬組成物
DOP2002000390A (es) * 2001-05-14 2003-03-15 Pfizer Prod Inc Sal citrato de 5,8 14-hiezatetraciclo [10.3.1.0 2,11. 0.4.9] hexadeca-2(11),3,5,8,9, pentaeno y composiciones farmaceuticas de las mismas
CA2468705A1 (en) * 2001-11-29 2003-06-05 Pfizer Products Inc. Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
DE60218885T2 (de) * 2001-11-30 2008-01-17 Pfizer Products Inc., Groton Orale pharmazeutische Arzneiformen bzw. Dosierungsformen von 5,8,14-Triazatetra-cyclo-(10.3.1.0 (2,11).0(4,9)-hexadeca-2(11),3,5,7,9-pentaen mit kontrollierter Freisetzung
EP1451202B1 (en) * 2001-11-30 2008-08-20 Pfizer Products Inc. Aryl fused azapolycyclic compounds
CA2533100A1 (en) * 2003-07-21 2005-01-27 Pfizer Products Inc. Aryl fused azapolycyclic compounds

Also Published As

Publication number Publication date
TR200001840T2 (tr) 2000-12-21
IS5514A (is) 2000-05-26
US20020132824A1 (en) 2002-09-19
HN1998000177A (es) 1999-02-09
CZ20002438A3 (cs) 2002-11-13
MA26589A1 (fr) 2004-12-20
NO20003422D0 (no) 2000-06-30
DE122008000038I1 (de) 2008-11-13
IL136727A0 (en) 2001-06-14
US20020072525A1 (en) 2002-06-13
LU91442I9 (me) 2018-12-31
EP1659114A2 (en) 2006-05-24
BR9814592A (pt) 2000-10-17
NO319115B1 (no) 2005-06-20
CA2316921A1 (en) 1999-07-15
EP1044189B1 (en) 2008-02-13
SI1044189T1 (sl) 2008-06-30
MY118163A (en) 2004-09-30
DZ2697A1 (fr) 2003-03-29
CO4810373A1 (es) 1999-06-30
ES2301210T3 (es) 2008-06-16
ES2301210T5 (es) 2015-05-07
FR08C0039I2 (fr) 2009-12-18
DE69839131T2 (de) 2009-02-05
GT199800200A (es) 2000-06-07
US20070275973A1 (en) 2007-11-29
JP3550359B2 (ja) 2004-08-04
BR9816186B1 (pt) 2009-01-13
TNSN98237A1 (fr) 2005-03-15
AR017967A1 (es) 2001-10-24
AU9641698A (en) 1999-07-26
HRP20050506A2 (en) 2006-03-31
NO2006016I1 (no) 2006-11-27
RS50069B (sr) 2009-01-22
DE69839131D1 (de) 2008-03-27
SI1044189T2 (sl) 2015-05-29
EP1044189B2 (en) 2015-02-25
CY1107391T1 (el) 2010-07-28
NL300355I2 (nl) 2008-11-03
NL300355I1 (nl) 2008-08-01
UA66825C2 (uk) 2004-06-15
DK1044189T4 (en) 2015-03-30
HRP20000445A2 (en) 2001-04-30
HUP0100949A2 (hu) 2001-08-28
PL209404B1 (pl) 2011-08-31
CY2008013I1 (el) 2009-11-04
ZA9811911B (en) 2000-06-29
AU753389C (en) 2007-08-09
NZ504482A (en) 2003-01-31
NO2006016I2 (me) 2008-10-20
SK286886B6 (sk) 2009-07-06
EA003190B1 (ru) 2003-02-27
HUP0100949A3 (en) 2002-12-28
US6951938B2 (en) 2005-10-04
US6887884B2 (en) 2005-05-03
US6897310B2 (en) 2005-05-24
AU753389B2 (en) 2002-10-17
HU230297B1 (hu) 2015-12-28
PA8463901A1 (es) 2000-09-29
US6410550B1 (en) 2002-06-25
US20020111350A1 (en) 2002-08-15
HUS1600018I1 (hu) 2018-05-02
SG102686A1 (en) 2004-03-26
KR20010033823A (ko) 2001-04-25
CA2316921C (en) 2004-12-07
GT199800200AA (es) 2000-06-07
CY2008013I2 (el) 2009-11-04
CN1324013C (zh) 2007-07-04
PE20000053A1 (es) 2000-02-07
WO1999035131A1 (en) 1999-07-15
EP1044189A1 (en) 2000-10-18
TW513412B (en) 2002-12-11
BG65058B1 (bg) 2007-01-31
EP1659114A3 (en) 2007-01-17
BR9814592B1 (pt) 2010-06-01
DE69839131T3 (de) 2015-05-07
PL341824A1 (en) 2001-05-07
IL136727A (en) 2006-06-11
ATE386024T1 (de) 2008-03-15
OA11428A (en) 2004-05-03
BG104561A (en) 2001-01-31
HK1031878A1 (en) 2001-06-29
JP2002500218A (ja) 2002-01-08
CZ301925B6 (cs) 2010-08-04
US20020072524A1 (en) 2002-06-13
AP1170A (en) 2003-06-30
NO20003422L (no) 2000-08-29
YU40300A (sh) 2003-10-31
EA200000592A1 (ru) 2000-12-25
KR100408138B1 (ko) 2003-12-01
DK1044189T3 (da) 2008-05-13
CN1715280A (zh) 2006-01-04
AP9801422A0 (en) 1998-12-31
LU91442I2 (fr) 2008-07-21
SA99191123B1 (ar) 2006-10-02
EG23816A (en) 2007-09-19
FR08C0039I1 (me) 2008-11-14
PT1044189E (pt) 2008-04-22
SK9712000A3 (en) 2002-03-05
CN1285821A (zh) 2001-02-28
HRP20000445B1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
ME00459B (me) Aril fuzirana azapoliciklična jedinjenja
CA2401229A1 (en) Aryl fused azapolycyclic compounds
BR9709823B1 (pt) &#34;compostos de amidas de ácido alqueno piridílico e alquino piridílico, métodos de preparação e uso dos mesmos, bem como medicamento&#34;.
NZ337118A (en) 3-piperidyl-4-oxoquinazoline derivatives and pharmaceutical compositions comprising the same useful in treating or preventing arteriosclerotic and/or hyper-lipemia disease, pancreatitis, obesity, hypercholesterolemia and hypertriglyceridemia.
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
BG66085B1 (bg) Фенилаланинови производни
EA200200421A1 (ru) АМИНОЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]-1,5-ПИРИМИДИНЫ И ПИРАЗОЛО[1,5-a]-1,3,5-ТРИАЗИНЫ
NO963850D0 (no) Heterosykliske forbindelser, deres fremstilling og anvendelse
LV12291A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai
HUP0002272A2 (hu) Piperazinszármazékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
FR2712591B1 (fr) Nouvelles arylpipérazines dérivées d&#39;indole, leur préparation et leur utilisation thérapeutique.
EA199700380A1 (ru) Бициклические ароматические соединения, фармацевтическая и косметическая композиции на их основе и применение косметической композиции
ATE269865T1 (de) Pyrazolo(3,4-g)chinoxaline als pdgf-rezeptor protein tyrosin-kinase inhibitoren
BG104983A (en) Aryl fused azapolycyclic compounds
YU42397A (sh) Korišćenje raloksifena za pripremu leka
HUP0201315A2 (hu) 4-Fenil-pirimidin-származékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények
ATE292117T1 (de) Zusammensetzungen zur behandlung von hautkrankheiten
DE69501359T2 (de) Verwendung von Phosphatdiestern zur Behandlung von Erkrankungen der Retina
FR2767527B1 (fr) Derives de piperazines indoliques, utiles comme medicaments et procede de preparation
KR960703912A (ko) 중추신경계 활성을 갖는 헤테로사이클 아민(heterocyclic amines having central nervous system activity)
GR3032950T3 (en) Substituted fused and bridged bicyclic compounds as therapeutic agents
SE9702716D0 (sv) Substituted phenylazacycloalkanes in the treatment of cognitive disorders
TR199900013T2 (xx) Yeni bile�ikler.
PT1025101E (pt) Derivados de nafto-imidazo¬1,2-a|piridina sua preparacao e uso no tratamento de perturbacoes do sistema nervoso central
ATE241985T1 (de) Therapeutisches mittel zur behandlung von nierenerkrankungen